Dose-dependent percent changes from baseline were observed across the placebo, simvastatin # mg and simvastatin # mg treatments for the primary end point (LDL cholesterol) and for the secondary end points (VLDL cholesterol, triglycerides, non HDL cholesterol, HDL cholesterol, apolipoprotein B, and apolipoprotein A-I
Si es para que no entienda Crispina, yo tampoco entiendoEMEA0.3 EMEA0.3